Enanta advances zelicapavir into Phase 2b/3 RSV trial following FDA meeting
Enanta Pharmaceuticals announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial for high-risk RSV adults, with Phase 2b data expected in 2027, plus a pediatric Phase 2b trial starting in Q3 2026. The company estimates the oral RSV antiviral market oppo
View filing at SEC.gov →